Straits Times Index
3,330.77 -0.04 (-0.00%) Nikkei
38,683.93 -19.58 (-0.05%) Hang Seng
18,366.95 -109.85 (-0.59%) FTSE 100
8,269.86 -15.48 (-0.19%) Bitcoin USD
71,362.01 -56.47 (-0.08%) CMC Crypto 200
1,487.50 +8.80 (+0.59%)
AB Science S.A. (0Q77.L)
- GlobeNewswire
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS). The webcast
- GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the treatment of amyot
- GlobeNewswire
AB Science reports its revenues for the year 2023 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional marketing authorisation application procedures with the European Medicines Agency (EMA) and Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)First complete bone marrow response in an acute myeloid leukemia patient in its AB8939 Phase I/II clinical trialNew clinical development program for masiti
